Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Deferred Taxes (2019)

Allogene Therapeutics' Deferred Taxes history spans 1 years, with the latest figure at $33000.0 for Q3 2019.

  • For Q3 2019, Deferred Taxes changed N/A year-over-year to $33000.0; the TTM value through Sep 2020 reached $33000.0, changed N/A, while the annual FY2018 figure was $41.9 million, N/A changed from the prior year.
  • Deferred Taxes for Q3 2019 was $33000.0 at Allogene Therapeutics, up from -$159000.0 in the prior quarter.
  • Across five years, Deferred Taxes topped out at $33000.0 in Q3 2019 and bottomed at -$159000.0 in Q2 2019.